Clinical Trials List
2011-10-01 - 2014-12-31
Phase II
Terminated11
-
Trial Applicant
National Health Research Institutes
-
Sponsor
-
Trial scale
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Li-Yuan Bai Division of Hematology & Oncology
- Mei-Due Yang Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chun-Nan Yeh Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ann-Lii Cheng Division of Hematology & Oncology
- 林育麟 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Li-Tzong Chen Division of Hematology & Oncology
- Nai-Jung Chiang Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Yan-Shen Shan Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 方文良 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 黃偉修 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 陳彥仰 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 謝瑞坤 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Hui-Hua Hsiao Division of Hematology & Oncology
- Ta-Chih Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
0 participants
